Exact Mass: 473.14006340000003

Exact Mass Matches: 473.14006340000003

Found 45 metabolites which its exact mass value is equals to given mass value 473.14006340000003, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Enasidenib

2-methyl-1-({4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl}amino)propan-2-ol

C19H17F6N7O (473.1399)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C137826 - Isocitrate Dehydrogenase Inhibitor > C168619 - IDH2 inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.

   

Lixivaptan

N-(3-chloro-4-{3,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),4,6,11,13-pentaene-9-carbonyl}phenyl)-5-fluoro-2-methylbenzamide

C27H21ClFN3O2 (473.1306)


C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist

   
   
   
   
   

Pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-trione,7-[2-(ethylsulfonyl)ethyl]-6-hydroxy-1,3-dimethyl-9-(phenylmethyl)-

Pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-trione,7-[2-(ethylsulfonyl)ethyl]-6-hydroxy-1,3-dimethyl-9-(phenylmethyl)-

C21H23N5O6S (473.1369)


   

NAN-190 hydrobromide

2-(4-(4-(2-METHOXYPHENYL)PIPERAZIN-1-YL)BUTYL)ISOINDOLINE-1,3-DIONE HYDROBROMIDE

C23H28BrN3O3 (473.1314)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists NAN-190 hydrobromide is a serotonin receptor 5-HT antagonist. NAN-190 is a selective antagonist of 5-HT1A[1][3].

   
   

Aluminon

Aurintricarboxylic acid ammonium salt

C22H23N3O9 (473.1434)


   

Pazopanib Hydrochloride

Pazopanib HCl (GW786034 HCl)

C21H24ClN7O2S (473.1401)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor

   

1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid

1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid

C23H21F6NO3 (473.1426)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D058805 - GABA Uptake Inhibitors D018377 - Neurotransmitter Agents > D018682 - GABA Agents D049990 - Membrane Transport Modulators

   

PDGF RTK inhibitor

PDGF RTK inhibitor

C26H23N3O4S (473.1409)


   

Lixivaptan

Lixivaptan

C27H21ClFN3O2 (473.1306)


C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist

   

Enasidenib

Enasidenib

C19H17F6N7O (473.1399)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C137826 - Isocitrate Dehydrogenase Inhibitor > C168619 - IDH2 inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.

   

[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[(3S)-3,6-diamino-2,6-dioxohexyl]phosphinic acid

[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[(3S)-3,6-diamino-2,6-dioxohexyl]phosphinic acid

C16H24N7O8P (473.1424)


   

Glutaminyl-beta-ketophosphonate-adenosine

Glutaminyl-beta-ketophosphonate-adenosine

C16H24N7O8P (473.1424)


   

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(E)-4-methyl-6-(3-methyl-1,4-dioxonaphthalen-2-yl)hex-4-enoyl]oxyoxane-2-carboxylate

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(E)-4-methyl-6-(3-methyl-1,4-dioxonaphthalen-2-yl)hex-4-enoyl]oxyoxane-2-carboxylate

C24H25O10- (473.1448)


   
   

N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide

N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide

C23H24ClN3O6 (473.1354)


   

1,2-dibutyryl-sn-glycero-3-phospho-(1D-myo-inositol)(1-)

1,2-dibutyryl-sn-glycero-3-phospho-(1D-myo-inositol)(1-)

C17H30O13P- (473.1424)


A 1-phosphatidyl-1D-myo-inositol(1-) that is the conjugate base of 1,2-dibutyryl-sn-glycero-3-phospho-1D-myo-inositol, obtained by deprotonation of the phosphate OH group; major species at pH 7.3.

   

3-[(2-Chlorophenyl)methyl]-7-[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]triazolo[4,5-d]pyrimidine

3-[(2-Chlorophenyl)methyl]-7-[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]triazolo[4,5-d]pyrimidine

C22H19ClF3N7 (473.1342)


   

2-[(2S,3R,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2S,3R,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-[(2R,3R,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2R,3R,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-[(2R,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2R,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-[(2R,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2R,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-[(2S,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2S,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-[(2S,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2S,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-[(2R,3R,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

2-[(2R,3R,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide

C23H24ClN3O6 (473.1354)


   

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1,3-dihydroxy-1-(2-hydroxyphenyl)propan-2-yl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1,3-dihydroxy-1-(2-hydroxyphenyl)propan-2-yl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C19H27N3O9S (473.1468)


   
   

CTX-0294885 (hydrochloride)

CTX-0294885 (hydrochloride)

C22H25Cl2N7O (473.1498)


CTX-0294885 hydrochloride is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 hydrochloride is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer[1].

   

(1r,2s,9r,10s,15r)-9,11,11',15-tetrahydroxy-7-methoxy-6'-methyl-3'-oxa-12-azaspiro[tetracyclo[8.3.3.0¹,¹⁰.0³,⁸]hexadecane-2,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),3(8),4,4',6,6',8',10',11-nonaen-13-one

(1r,2s,9r,10s,15r)-9,11,11',15-tetrahydroxy-7-methoxy-6'-methyl-3'-oxa-12-azaspiro[tetracyclo[8.3.3.0¹,¹⁰.0³,⁸]hexadecane-2,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),3(8),4,4',6,6',8',10',11-nonaen-13-one

C27H23NO7 (473.1474)


   

[(2r,3s,4s,5r,6s)-6-{4-[(s)-cyano(hydroxy)methyl]phenoxy}-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

[(2r,3s,4s,5r,6s)-6-{4-[(s)-cyano(hydroxy)methyl]phenoxy}-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

C23H23NO10 (473.1322)


   

(2s)-2-[(z)-{1-[(2r)-10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl]ethylidene}amino]pentanedioic acid

(2s)-2-[(z)-{1-[(2r)-10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl]ethylidene}amino]pentanedioic acid

C23H23NO10 (473.1322)


   

(2r,3s,4r,5r,6s)-6-{4-[(s)-cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

(2r,3s,4r,5r,6s)-6-{4-[(s)-cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

C23H23NO10 (473.1322)


   

(2r,3s,4r,5r,6s)-6-{4-[cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

(2r,3s,4r,5r,6s)-6-{4-[cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

C23H23NO10 (473.1322)


   

6-{4-[cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate

6-{4-[cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate

C23H23NO10 (473.1322)


   

(2s)-2-[(e)-{1-[(2r)-10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl]ethylidene}amino]pentanedioic acid

(2s)-2-[(e)-{1-[(2r)-10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl]ethylidene}amino]pentanedioic acid

C23H23NO10 (473.1322)


   

methyl 1-[2-(2-hydroxy-4-methoxyphenyl)-2-oxoethyl]-3,4-bis(4-hydroxyphenyl)pyrrole-2-carboxylate

methyl 1-[2-(2-hydroxy-4-methoxyphenyl)-2-oxoethyl]-3,4-bis(4-hydroxyphenyl)pyrrole-2-carboxylate

C27H23NO7 (473.1474)


   

(2s)-2-({1-[(2r)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),6,10,12-tetraen-4-ylidene]ethyl}amino)pentanedioic acid

(2s)-2-({1-[(2r)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),6,10,12-tetraen-4-ylidene]ethyl}amino)pentanedioic acid

C23H23NO10 (473.1322)


   

(2r)-2-({1-[(2r)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),6,10,12-tetraen-4-ylidene]ethyl}amino)pentanedioic acid

(2r)-2-({1-[(2r)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),6,10,12-tetraen-4-ylidene]ethyl}amino)pentanedioic acid

C23H23NO10 (473.1322)


   

(6-{4-[cyano(hydroxy)methyl]phenoxy}-3,4,5-trihydroxyoxan-2-yl)methyl 3-(3,4-dihydroxyphenyl)prop-2-enoate

(6-{4-[cyano(hydroxy)methyl]phenoxy}-3,4,5-trihydroxyoxan-2-yl)methyl 3-(3,4-dihydroxyphenyl)prop-2-enoate

C23H23NO10 (473.1322)


   

2-[(1-{10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl}ethylidene)amino]pentanedioic acid

2-[(1-{10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl}ethylidene)amino]pentanedioic acid

C23H23NO10 (473.1322)


   

(2s)-n-{[(2r,3s,4r,5r)-5-(6-amino-8-hydroxypurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(methoxy)phosphoryl}pyrrolidine-2-carboximidic acid

(2s)-n-{[(2r,3s,4r,5r)-5-(6-amino-8-hydroxypurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(methoxy)phosphoryl}pyrrolidine-2-carboximidic acid

C16H24N7O8P (473.1424)